2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J Lenihan, Gregory Y H Lip, Alexander R Lyon, Teresa Lopez Fernandez, Dania Mohty, Massimo F Piepoli, Juan Tamargo, Adam Torbicki, Thomas M Suter, Jose Luis Zamorano, Victor Aboyans, Stephan Achenbach, Stefan AgewallLina Badimon, Gonzalo Barón-Esquivias, Helmut Baumgartner, Jeroen J Bax, Héctor Bueno, Scipione Carerj, Veronica Dean, Çetin Erol, Donna Fitzsimons, Oliver Gaemperli, Paulus Kirchhof, Philippe Kolh, Patrizio Lancellotti, Petros Nihoyannopoulos, Massimo F Piepoli, Piotr Ponikowski, Marco Roffi, Adam Torbicki, António Vaz Carneiro, Stephan Windecker, Authors/Task Force Members

Research output: Contribution to journalArticlepeer-review

133 Citations (Scopus)

Abstract

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to John Wiley & Sons, the publisher of the European Journal of Heart Failure and the party authorized to handle such permissions on behalf of the ESC ([email protected]). Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Original languageEnglish
Pages (from-to)9-42
JournalEuropean Journal of Heart Failure
Volume19
Issue number1
Early online date27 Aug 2016
DOIs
Publication statusPublished - Jan 2017

Keywords

  • European Society of Cardiology
  • chemotherapy
  • cardiotoxicity
  • cardio-oncology
  • myocardial dysfunction
  • arrhythmias
  • ischaemia
  • early detection
  • surveillance
  • cancer therapy

Fingerprint

Dive into the research topics of '2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)'. Together they form a unique fingerprint.

Cite this